Search | Clinical Trials Finder

Conditions: Ventral Hernia, Umbilical Hernia, Incisional Hernia, Postoperative Complications, Pain, Postoperative
Interventions: Transabdominal Plane Block, Non Transabdominal Plane Block; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: MF-59, A/Anhui/05, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 637 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Conditions: Bunion, Pain
Interventions: Tapentadol, Matching Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hyperlipidemia
Interventions: Tetraethylammonium (TEA), L-NG-monomethyl Arginine (L-NMMA), Bradykinin, Sodium nitroprusside, Acetylcholine, Saline, Fluconazole; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cough, Nerve Block
Interventions: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline); Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chondral Lesion of the Knee, Meniscal Injuries, Cartilage Defects of the Knee, Osteoarthritis (OA) of the Knee
Interventions: Bone Marrow Aspirate (BMA), Arthroscopic Debridement Surgery, Saline; Biological · Procedure · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Anesthesia, Local
Interventions: Lidocaine 2%, Lidocaine 1%, Bupivacaine 0.25%, Bupivacaine 0.5%, Intralipid, 20% Intravenous, Saline intravenously, Saline; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Fracture of Ankle
Interventions: Dexamethasone, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine, Facial Pain or Pressure, Headache
Interventions: Topical solution of 4% lidocaine, Saline 0.9%; Drug
Lead sponsor: Association of Migraine Disorders; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Pulmonary Veno Occlusive Disease
Interventions: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec); Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ehlers-Danlos Syndrome, Anesthesia, Local
Interventions: 0.9% Sodium Chloride Injection, Lidocaine Injection 2%, Bupivacaine Injection 0.5%; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
Interventions: Hyaluronic Acid (HA), Tranexamic Acid (TXA), Saline (placebo); Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: CABG
Interventions: Placebo, GLP-1 (7-36) amide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Partial Thickness Rotator Cuff Tears
Interventions: TPX-115, Cryopreserving hyaluronic acid medium, Saline; Biological · Other · Drug
Lead sponsor: Tego Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois

Conditions: Progressive Supranuclear Palsy
Interventions: BIIB092, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 41 Years to 86 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 13 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Alport Syndrome
Interventions: RG012; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: La Mesa, California • Los Angeles, California • Riverside, California + 4 more

Conditions: Multiple Myeloma
Interventions: Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Tetrodotoxin, Placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more

Conditions: Sepsis, Septic Shock, Metabolic Disturbance
Interventions: vitamin C, vitamin B1, hydrocortisone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more

Conditions: Myasthenia Gravis, Generalized
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more

Conditions: Bacterial Disease Carrier, Cystic Fibrosis
Interventions: Placebo, WRAIR-PAM-CF1; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Search by objective public record fields.

Does a Transabdominal Plane Block Decrease Patient Pain After Ventral Hernia Repair?

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Intravenous Tapentadol in Post-Bunionectomy Pain

Endothelial Hyperpolarization in Humans

Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough

Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

Intralipid® 20% for Reversal of Local Anesthetics

Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block

Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers

Effect of TXA on Reducing Bruising After Filler Injection

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

A Study of RG-012 in Subjects With Alport Syndrome

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa